You searched for Switzerland - Page 34 of 39

News and Trends 31 Aug 2016

Novartis’ second FDA Biosimilar Approval could unlock Billions

Novartis just attained FDA approval for a second biosimilar in the US. Erelzi will unlock the €4.5B rheumatoid arthritis market cornered by Enbrel. Sandoz, a division of Novartis based in…

August 31, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 2 May 2017

Novartis Gains Access to Celyad’s allogenic CAR-T cell patents

Belgian Celyad is giving Novartis access to its IP for the production of allogeneic CAR-T cells in a non-exclusive license agreement, worth up to €88M. Celyad is developing “off-the-shelf” therapies,…

May 2, 2017 - 2 minutesmins - By Melanie De Almeida

oxford biotech biomedica novartis car t cancer

News and Trends 1 Feb 2016

World CAR-T Leader Starts New Program with a UK Biotech

Pretty impressive CAR-T news coming from across the Channel… Oxford BioMedica just launched a second collaboration with Novartis, which has shown tremendous Phase II results – and the most advanced…

February 1, 2016 - 2 minutesmins - By Philip Hemme

News and Trends 29 Aug 2022

Marketing authorization granted for treatment of serious retinal diseases

The European Commission has granted marketing authorization to Ranivisio, a treatment for several serious retinal diseases. Polpharma Biologics Group BV, Formycon AG and their Swiss joint venture, Bioeq AG, announced…

August 29, 2022 - 3 minutesmins - By Liza Laws

News and Trends 15 Sep 2017

Swiss-US Partners Reveal New Candidate for Autoimmune Disease

Numab and Intarcia have a first candidate to combine a tri-specific antibody fragment with a mini-osmotic pump delivery system to fight autoimmune disease. Numab and Intarcia partnered in 2015 to…

September 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Apr 2018

Gene Therapy For Beta-Thalassemia Could Eliminate Need for Transfusions

Bluebird bio has obtained results from two clinical studies showing its new gene therapy could eliminate the need for red blood cell transfusions in patients with beta-thalassemia. The company plans…

April 20, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 12 Sep 2022

Cuffless device worn 24/7 can lower blood pressure, says Aktiia

A company making cuffless monitors for blood pressure says a significant and sustained reduction has been achieved for patients wearing the monitor 24/7. The device, made by Aktiia, measures blood…

September 12, 2022 - 2 minutesmins - By Liza Laws

News and Trends 20 Sep 2016

UPDATE: Novartis is Favoured to Win the Race for a New MS Drug

Novartis is poised to kick off the next generation of multiple sclerosis treatments after siponimod performs well in Phase III. The company’s primary competitor had been Biogen, but its drug’s…

September 20, 2016 - 2 minutesmins - By Evelyn Warner

Interview 31 Aug 2022

How CDMOs keep pace with trends in advanced therapies

Advanced therapies including cell and gene therapies are exploding in demand, but the manufacturing process can be difficult. Jean-Christophe Hyvert, president of biologics and cell & gene at the CDMO…

August 31, 2022 - 8 minutesmins - By Jonathan Smith

News and Trends 24 May 2017

French Biotech Enters New Agreement to Advance its IBD Immunotherapy

OSE Immunotherapeutics has teamed up with Selexis in a new license agreement to support the development of its IL-7 antagonist for the treatment of IBD. In the end of last…

May 24, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 23 Jan 2017

A Placebo beats the Largest European Biotech in Phase III

Actelion’s lead drug Opsumit has missed its primary endpoint in Phase III. What are the consequences for the biggest independent biotech in Europe? Actelion is a leader in treatments for…

January 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Molecular Partners drug development cancer

Interview 16 May 2019

Taking a Drug to Market “Is a Marathon, Not a Sprint”

Based in Zurich, Molecular Partners is developing a new class of drugs that can address the complexity of cancer. At Labiotech Refresh in Zurich, CEO Patrick Amstutz shared what he’s…

May 16, 2019 - 4 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Switzerland

Novartis’ second FDA Biosimilar Approval could unlock Billions

Novartis Gains Access to Celyad’s allogenic CAR-T cell patents

World CAR-T Leader Starts New Program with a UK Biotech

Marketing authorization granted for treatment of serious retinal diseases

Swiss-US Partners Reveal New Candidate for Autoimmune Disease

Gene Therapy For Beta-Thalassemia Could Eliminate Need for Transfusions

Cuffless device worn 24/7 can lower blood pressure, says Aktiia

UPDATE: Novartis is Favoured to Win the Race for a New MS Drug

How CDMOs keep pace with trends in advanced therapies

French Biotech Enters New Agreement to Advance its IBD Immunotherapy

A Placebo beats the Largest European Biotech in Phase III

Taking a Drug to Market “Is a Marathon, Not a Sprint”

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!